BioPharmSignal logoBioPharmSignal

Biotech News

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Corvus Pharmaceuticals (CRVS)Corvus PharmaceuticalsFinancing

$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in development by Corvus in the United States SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) --

Related news

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

ERASErasca2026-07-15 20:01 EST

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

CRVSCorvus Pharmaceuticals2026-08-06 20:01 EST

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results

CRVSCorvus Pharmaceuticals2026-07-30 20:01 EST

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026

ERASErasca2026-07-14 03:10 EST

Erasca Announces Pricing of Upsized Public Offering of Common Stock

ELVNEnliven Therapeutics2026-06-12 02:39 EST

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

IDYAIDEAYA Biosciences2026-06-10 20:05 EST

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SNDXSyndax Pharmaceuticals2026-06-04 11:00 EST

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

LEGNLegend Biotech Corporation2026-06-18 01:21 EST

Legend Biotech Corporation Announces Pricing of Public Offering

LEGNLegend Biotech Corporation2026-06-17 20:29 EST

Legend Biotech Corporation Announces Proposed Public Offering

View all latest news

Corvus Pharmaceuticals

ITK Inhibition Corvus Pharmaceuticals develops therapies based on inhibition of interleukin-2-inducible T-cell kinase, or ITK. The approach is intended to rebalance immune-cell activity in inflammatory diseases and cancer. Soquelitinib Soquelitinib is an oral, selective ITK inhibitor. Its lead immunology program is a Phase 2 study in...

Recent company news

CRVSCorvus Pharmaceuticals2026-08-06 20:01 EST

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results

CRVSCorvus Pharmaceuticals2026-07-30 20:01 EST

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026

CRVSCorvus Pharmaceuticals2026-06-09 11:30 EST

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

CRVSCorvus Pharmaceuticals2026-05-20 20:01 EST

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

CRVSCorvus Pharmaceuticals2026-05-14 11:00 EST

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

Stock data

Close
13.86 USD
Market cap
983.02M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States